Pegylated interferon alpha-2a

DRUG6 trials

Sponsors

Alexion Pharmaceuticals, Inc., Janssen R&D Ireland, GlaxoSmithKline, King Abdulaziz Medical City, Markus Peck-Radosavljevic

Conditions

Chronic Hepatitis C VirusHIVHepatitis CHepatitis C Virus Genotype 4 InfectionHepatitis C Virus Genotype-1Hepatitis C, Chronic

Phase 2

Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants

CompletedNCT01180790

Alexion Pharmaceuticals, Inc.Hepatitis C

Start: 2010-09-30End: 2013-04-30Updated: 2023-08-30

Dose Ranging of GSK2336805 in Combination Therapy

CompletedNCT01648140

GlaxoSmithKlineHepatitis C, Chronic

Start: 2012-08-01End: 2014-07-16Updated: 2017-06-02

Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)

CompletedNCT02107365

ANRS, Emerging Infectious DiseasesHepatitis C Virus Genotype 4 Infection

Start: 2013-11-30End: 2015-04-30Updated: 2017-01-24

Phase 3

A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1

CompletedNCT01479868

Janssen R&D IrelandHepatitis C Virus Genotype-1

Start: 2011-10-31End: 2013-08-31Updated: 2014-10-29

Phase 4

Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4

CompletedNCT01686789

King Abdulaziz Medical CityChronic Hepatitis C Virus

Start: 2011-01-31End: 2015-08-31Updated: 2016-02-24

Individualized Triple-therapy Using Boceprevir in HIV-positive Patients With Hepatitis C

CompletedNCT01925183

Markus Peck-RadosavljevicHepatitis C, Chronic, HIV

Start: 2013-08-31End: 2015-06-30Updated: 2017-03-16

Related Papers

Simeprevir with pegylated interferon alfa 2a plus ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a meta-analysis and historical comparison.

2016-01-114 citations

How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?

2016-01-0661 citations

Response-guided boceprevir-based triple therapy in HIV/HCV-coinfected patients: the HIVCOBOC-RGT study.

2014-09-119 citations

Simeprevir (TMC435) With Pegylated Interferon/Ribavirin in Patients Coinfected With HCV Genotype 1 and HIV-1: A Phase 3 Study

Clinical Infectious Diseases2014-09-0567 citations